Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

TYPE OF SARCOMA: Dermatofirbrosarcoma Protuberans
DRUG: Gleevec (Imatinib Mesylate)
ACCRUAL STATUS: Completed

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Scott Schuetze, MD, PhD
University of Michigan

CLINICALTRIALS.GOV IDENTIFIER: NCT00243191

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study or to contact the study research staff: